Application study of PDX modeling and MiniPDX drug sensitivity test in individualized precision medicine for malignant tumor patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027396

Enrollment

Unknown

Registered

2019-11-11

Start date

2019-11-11

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi-cancer types

Interventions

malignant tumor cases:MiniPDX drug sensitivity test

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: 1. cancer patients diagosed with histopathology, aged 18-75 years old; 2. Fresh tumor samples can be obtained through surgury, centesis or pleural effusion and ascites; 3. Have tumors meeting RECIST 1.1 standard and the clinical efficacy can be evaluated using CT/MRI; 4. ECOG score =3 months; 5. Subjects are voluntary to be involved in this trial and sign informed consent form; have good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients who have incomplete clinical information; 2. Patients who undergo unplanned second surgery after first surgery; 3. Patients who are discovered to have second cancer during treatment process, which may interfere this trial.

Design outcomes

Primary

Measure	Time frame
Objective response rate;Progression-free survival;overall survival;	—

Secondary

Measure	Time frame
Quality of life;	—

Countries

China

Contacts

Public ContactWen Danyi

Shanghai LIWEN Biotech Co., Ltd

danyi.wen@lidebiotech.com+86 021-68587010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026